Thomas E Stinchcombe

Summary

Affiliation: University of North Carolina
Country: USA

Publications

  1. Weiss J, Villaruz L, Socinski M, Ivanova A, Grilley Olson J, Dhruva N, et al. A single-arm phase II trial of pazopanib in patients with advanced non-small cell lung cancer with non-squamous histology with disease progression on bevacizumab containing therapy. Lung Cancer. 2014;86:288-90 pubmed publisher
    ..Pazopanib has limited activity in NSCLC-NS in patients who have experienced disease progression on bevacizumab. ..
  2. Stinchcombe T, Johnson G. MEK inhibition in non-small cell lung cancer. Lung Cancer. 2014;86:121-5 pubmed publisher
    ..Other potential explanations are gene amplifications, alternative RNA splicing of genes resulting in activation of their protein products, and deregulation of noncoding RNAs and consequent altered protein expression. ..
  3. Stinchcombe T, Socinski M, Lee C, Hayes D, Moore D, Goldberg R, et al. Phase I trial of nanoparticle albumin-bound paclitaxel in combination with gemcitabine in patients with thoracic malignancies. J Thorac Oncol. 2008;3:521-6 pubmed publisher
    ..The maximum tolerated dose of nab-paclitaxel is 300 mg/m in combination with gemcitabine 1000 mg/m on days 1, 8 every 21 days. This combination demonstrated activity in previously treated NSCLC and SCLC patients. ..
  4. Stinchcombe T, Socinski M. Gefitinib in advanced non-small cell lung cancer: does it deserve a second chance?. Oncologist. 2008;13:933-44 pubmed publisher
    ..Results of recent gefitinib trials have been provocative, and suggest a role for gefitinib in the treatment of advanced NSCLC. ..
  5. Stinchcombe T, Bogart J, Wigle D, Govindan R. Annual review of advances in lung cancer clinical research: a report for the year 2009. J Thorac Oncol. 2010;5:935-9 pubmed publisher
    ..In limited-stage small cell lung cancer, a phase III trial compared standard and high-dose prophylactic cranial irradiation and revealed no significant difference in the rate of brain metastases between the two treatment arms. ..
  6. Stinchcombe T, Borghaei H, Barker S, Treat J, Obasaju C. Pemetrexed With Platinum Combination as a Backbone for Targeted Therapy in Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2016;17:1-9 pubmed publisher
    ..This review aims to summarize the current knowledge and future prospects of the use of pemetrexed-platinum as a backbone for combination with targeted therapies for NSCLC. ..
  7. Grilley Olson J, Keedy V, Sandler A, Moore D, Socinski M, Stinchcombe T. A randomized phase II study of carboplatin with weekly or every-3-week nanoparticle albumin-bound paclitaxel (abraxane) in patients with extensive-stage small cell lung cancer. Oncologist. 2015;20:105-6 pubmed publisher
    ..The trial was closed because of slow accrual. Carboplatin and nab-paclitaxel demonstrated activity in ES-SCLC but required frequent dose adjustments. ..
  8. Stinchcombe T, Gore E. Limited-stage small cell lung cancer: current chemoradiotherapy treatment paradigms. Oncologist. 2010;15:187-95 pubmed publisher
  9. Stinchcombe T, Der C. Are all KRAS mutations created equal?. Lancet Oncol. 2011;12:717-8 pubmed publisher

More Information

Publications12

  1. Stinchcombe T, Cella D. Does maintenance pemetrexed maintain quality of life?. Lancet Oncol. 2012;13:224-5 pubmed publisher
  2. Stinchcombe T. The Use of EGFR Tyrosine Kinase Inhibitors in EGFR Wild-Type Non-Small-Cell Lung Cancer. Curr Treat Options Oncol. 2016;17:18 pubmed publisher
    ..I suspect that the use of EGFR TKIs in clinical use and as a comparator arm for clinical trials will continue to decline over the next several years. ..
  3. Stinchcombe T. Targeted Therapies for Lung Cancer. Cancer Treat Res. 2016;170:165-82 pubmed publisher
    ..A phase III trial of cisplatin and gemcitabine with and without necitumumab in patients with advanced NSCLC with squamous histology demonstrated a statistically significant improvement in progression-free and overall survival. ..